<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4115">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04690920</url>
  </required_header>
  <id_info>
    <org_study_id>UOL/IMBB/2020/118</org_study_id>
    <nct_id>NCT04690920</nct_id>
  </id_info>
  <brief_title>Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins</brief_title>
  <official_title>Theranostic Implication of Complimentary Medicines Against IL-6/Gp-130 in COVID-19.: An in Vitro and in Silco Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Lahore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Lahore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      IL-6 is an inflammatory marker, secrete by the cells in many pathological conditions like&#xD;
      COVID-19 pneumonia. Interleukin 6 bind with its receptors (IL-6R) on cells surface and&#xD;
      recruited a protein for its activation known as gp-130. Activated receptors send signals to&#xD;
      nucleus through secondary messenger system and up regulate the expression of IL-6/GP130&#xD;
      domain. Total of two hundred (n=200) participants were included in the current study and&#xD;
      divided equally in four groups. Group B is given Tocilizumab and Group C is treated with&#xD;
      Remdesivir along with the approved standard treatment. Group D is only Given standard therapy&#xD;
      and Group A constituted normal healthy age and sexed matched participants. Levels of gp-130&#xD;
      were estimated by commercially available ELISA kit. To estimate the relationship of severity&#xD;
      of disease with gp-130 and IL-6 Pearson's correlations was used. Sensitivity and specificity&#xD;
      for what purpose&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 23, 2020</start_date>
  <completion_date type="Actual">December 10, 2020</completion_date>
  <primary_completion_date type="Actual">December 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen demand</measure>
    <time_frame>7-15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>7-15 days</time_frame>
    <description>by RT-PCR</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Corona Virus Disease 2019 (COVID-19)</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tocilizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Remdesivir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls</description>
    <arm_group_label>Remdesivir</arm_group_label>
    <arm_group_label>Standard Treatment</arm_group_label>
    <arm_group_label>Tocilizumab</arm_group_label>
    <other_name>Remdesivir</other_name>
    <other_name>Standard treatment with Antibiotic, oxygen, Vitamin C, Statins</other_name>
    <other_name>No treatment is given to control group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Admitted diagnosed cases of COVID-19 infection on real time polymerase chain reaction&#xD;
        (RT-PCR) Both male and female were included All participants were on oxygen therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Asthmatics pulmonary fibrosis chronic obstructive pulmonary disease (COPD) Allergic to&#xD;
        remdesivir Allergic to Actemra Refused to take consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male and female diagnosed as COVID-19 infected by polymerase chain reaction (PCR)</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arif Malik, PhD</last_name>
    <role>Study Director</role>
    <affiliation>The University of Lahore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Lahore</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <zip>54000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 19, 2020</study_first_submitted>
  <study_first_submitted_qc>December 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Lahore</investigator_affiliation>
    <investigator_full_name>Dr Muhammad Mansoor Hafeez</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>corona virus disease 2019 (COVID-19)</keyword>
  <keyword>Tocilizumab</keyword>
  <keyword>Remdesivir</keyword>
  <keyword>Interleukin receptor-6, glycoprotein-130</keyword>
  <keyword>receptor blocker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>statistical analysis, results</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

